{"filing":{"accession_number":"0001437749-26-019102","cik":"0001668243","ticker":"URGN","company_name":"UroGen Pharma Ltd.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"urgn20260601_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/urgn20260601_8k.htm"},"events":[{"id":7547,"run_id":6632,"accession_number":"0001437749-26-019102","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"summary":"UroGen disclosed settlement and termination of patent litigation with Teva regarding Jelmyto, resolving a dispute over a generic ANDA submission. The settlement grants Teva a non-exclusive license to sell generic Jelmyto beginning September 15, 2030, and terminates all ongoing patent litigation in the U.S. District Court for the District of Delaware. This material litigation settlement directly affects the Company's competitive position and revenue protection for a key product.","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-02","submitted_at":null,"items":[{"id":3680,"accession_number":"0001437749-26-019102","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"UroGen disclosed settlement and termination of patent litigation with Teva regarding Jelmyto, resolving a dispute over a generic ANDA submission. The settlement grants Teva a non-exclusive license to sell generic Jelmyto beginning September 15, 2030, and terminates all ongoing patent litigation in the U.S. District Court for the District of Delaware. This material litigation settlement directly affects the Company's competitive position and revenue protection for a key product.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:39:44.720591+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3680,"accession_number":"0001437749-26-019102","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"UroGen disclosed settlement and termination of patent litigation with Teva regarding Jelmyto, resolving a dispute over a generic ANDA submission. The settlement grants Teva a non-exclusive license to sell generic Jelmyto beginning September 15, 2030, and terminates all ongoing patent litigation in the U.S. District Court for the District of Delaware. This material litigation settlement directly affects the Company's competitive position and revenue protection for a key product.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:39:44.720591+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-02"}]}